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Abstract.
BACKGROUND: Progressive MS is associated with a high frequency of cognitive impairment. However, it is not clear to what
extent this reflects global dysfunction, or independent deficits in specific functions.
OBJECTIVE: To characterise patterns of cognitive impairment in progressive MS on a multi-dimensional cognitive assessment
tool well established in neurodegenerative diseases.
METHODS: Patients with secondary (SPMS; n = 60) and primary progressive MS (PPMS; n = 28) were assessed using the
Addenbrooke’s Cognitive Examination-Revised (ACE-R) multi-dimensional cognitive assessment scale. Independent dimensions
of impairment and their relative contribution to the overall burden of cognitive dysfunction were then determined by factor
analysis.
RESULTS: Two independent dimensions of impairment were seen: frontal-executive (attention, verbal fluency, recall) on one
hand, and language and visuospatial functions on the other. These accounted for 55% and 45% respectively of the variance not
explained by a global influence (14.2% and 11.6% respectively of total variance). Isolated language and visuospatial dysfunction
was seen in both groups, whereas isolated impairment in frontal-executive functions was underrepresented in SPMS (p = 0.001)
and not seen in PPMS patients (p = 0.040).
CONCLUSIONS: In addition to a prominent global influence on cognitive performance, patients with progressive MS com-
monly exhibit language and visuospatial deficits. Evaluation of these abilities should therefore be included in clinical assessment
of cognition in progressive MS.
Keywords: Multiple sclerosis, clinical trials observational study, assessment of cognitive disorders/dementia, neuropsychological
assessment
1. Introduction
Multiple sclerosis (MS) is the commonest non-
traumatic cause of acquired disability amongst young
European adults [1], with cognitive impairment seen
in 40–70% of cases [2]. Reduced speed of informa-
tion processing, together with impairment in executive
functions, recall memory, and attention are the most
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frequently described deficits [3,4], particularly in the
most extensively studied patient group with relapsing-
remitting disease. In comparison, language and visu-
ospatial functions have received less attention, despite
evidence of involvement in large cohort studies [5]
as well as in studies specifically assessing these do-
mains [6,7]. It therefore remains unclear whether cog-
nitive dysfunction in MS always reflects a universal
deficit of all functions, or whether impairment of spe-
cific functions can occur independently. The question
has practical implications for the choice of appropriate
assessment instruments. In the first case, the cognitive
impairment is best measured by current batteries, fo-
cused on the speed of information processing and ex-
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ecutive functions [8,9]. In the second case, preference
should be given to tests distinguishing specific impair-
ments of individual cognitive domains.
This issue is particularly relevant for the less-
researched progressive forms of the disease. A neu-
rodegenerative component of pathology is increasingly
recognized in all forms of MS, but may be particu-
larly salient to the progressive phase [10,11]. Neuro-
axonal damage and loss in the context of progressive
disease therefore represents a possible pathological ba-
sis for differences in the clinical features of cognitive
impairment between patients with (early) relapsing-
remitting disease and those in the progressive phase.
Indeed, previous studies in this area suggest that pro-
gressive disease may be particularly associated with
impairments in visuospatial abilities and information
processing speed [12–14].
Growing recognition of a neurodegenerative com-
ponent in MS pathology [15], also raises the question
whether research on cognitive aspects of MS could
benefit from the insights gained in recent years through
the study of other neurodegenerative diseases, partic-
ularly in terms of defining specific patters of cogni-
tive impairment characterising individual disease enti-
ties [16–18]. However, one of the main difficulties in
comparing MS with neurodegenerative syndromes is
the different assessment tools used in these conditions.
We therefore decided to examine patients with progres-
sive MS using one of the best established and most
successful cognitive screening tools used in neurode-
generation: the Addenbrooke’s Cognitive Examination
Revised (ACE-R). The ACE-R is a sensitive clinical
tool for the multi-domain assessment of cognition, in-
cluding language and visuospatial functions [19]. It
comprises a 100-point assessment of orientation and
attention (18-points), memory (26-points), verbal flu-
ency (14-points), language (26-points), and visuospa-
tial function (16-points). The ACE-R is a practical bed-
side tool that has been validated and widely applied
for the assessment of cognition in neurodegenerative
diseases with cortical and subcortical pathology in-
cluding Alzheimer’s disease [16], frontotemporal de-
mentia [16], dementia with Lewy bodies [17], primary
progressive aphasia [20], multisystem atrophy, cor-
ticobasal degeneration, and progressive supranuclear
palsy [18]. Studies comparing performance with an-
other well-established cognitive screening tool, the De-
mentia Rating Scale (DRS), demonstrated that ACE,
despite being shorter and easier to use, reached equal
levels of sensitivity in detecting cognitive impair-
ment [17,18]. By using multivariate statistical analy-
sis, we evaluated the contribution of global dysfunc-
tion and dysfunction in specific mental abilities to the
overall pattern of cognitive impairment in progressive
MS.
2. Methods
Participants were recruited from a research clinic for
patients with progressive MS in Cambridge, UK. Ap-
proval was obtained from the local ethics committee
and all patients gave written informed consent.
2.1. Recruitment of subjects
Patients were recruited from the East Anglia and
North London regions of the UK. Eligibility criteria
were: revised (2005) McDonald criteria MS [21] and a
progressive disease course. Eighty-seven control sub-
jects without known neurological or psychiatric disor-
der were also recruited locally. A matched control co-
hort was then achieved through stratified sampling by
age, gender and educational level (n = 24).
2.2. Assessment schedule
Patients were assessed at a single visit by neurolog-
ical history and examination. Data was not collected
on previous disease modifying therapy use. Cognitive
function was evaluated using the Addenbrooke’s Cog-
nitive Examination (Revised) (ACE-R). All cognitive
assessments were performed by PC. In brief, assess-
ment of each cognitive domain comprised the follow-
ing:
Attention and orientation: (18 points) Orientation in
time and space, registration of three words and serial
subtraction/backwards spelling.
Memory: (26 points) Recall of three words (1
minute) and recall of fictitious name and address (im-
mediate and after 10 mins), and four general knowl-
edge questions.
Verbal fluency: (14 points) Spontaneous generation
of words over one minute defined by initial letter (P)
and semantic category (animals).
Language: (26 points) Written and verbal compre-
hension (one and three-step), writing ability, repetition
of words and phrases, object-recognition and naming,
reading ability.
Visuospatial: (16 points) Copying of overlapping
pentagons and wire cube, generation of a clock face,
dot counting and naming incomplete letters.
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Table 1
Participant characteristics
MS disease course
SPMS PPMS All p
n 60 28 88 −
Age (mean, SD) 50.8 (8.8) 51.3 (11.2) 50.9 (9.6) 0.54
Male sex (%) 56.7 53.6 55.7 0.79∗
Years in full-time education (mean, SD) 13.1 (2.9) 12.6 (2.7) 12.9 (2.8) 0.43
Disease duration in years (mean, SD) 13.6 (7.8) 9.4 (5.6) 12.3 (7.4) 0.02
Total MSIS-29 (mean, SD) 85.3 (21.6) 84.4 (21.7) 85 (21.5) 0.57
MSIS-29 physical sub-score (mean, SD) 63.0 (16.8) 62.9 (15.7) 63.0 (16.3) 0.69
MSIS-29 psychological sub-score (mean, SD) 22.3 (7.6) 21.5 (8.2) 22.0 (7.8) 0.41
EDSS (mean, SD) 5.9 (1.2) 5.7 (1.5) 5.8 (1.3) 0.43
BDI-II (mean, SD) 15.3 (14.0) 14.2 (9.6) 14.9 (12.7) 0.89
PASAT score (mean, SD) 39.0 (12.1) 35.0 (14.1) 37.8 (12.7) 0.18
ACE-R score (mean, SD) 91.6 (7.8) 89.4 (8.3) 90.9 (8.3) 0.08
SD= Standard deviation, MSIS-29=Multiple Sclerosis Impact Scale 29, EDSS= Expanded Kurtzke Disability Status Scale, BDI-II= Beck’s
Depression Index (II), ACE-R= Addenbrooke’s Cognitive Examination (Revised), PASAT= Paced Auditory Serial Addition Test. Significance
tests shown for equivalence between SPMS and PPMS, performed by Mann-Whitney except (*) = Pearson’s χ2 test.
Further assessment included: The multiple sclerosis
impact scale-29 (MSIS-29), Beck depression inventory
(II) (BDI-II), expanded disability status scale (EDSS),
and the 3-second paced auditory serial additions test
(PASAT).
2.3. Statistics
Analyses were performed using Stata SE (Version 9,
Stata Corp. TX, USA). Group comparisons for partic-
ipant characteristics were performed using the Mann-
Whitney U-test and Pearson’s χ2 test. Independent di-
mensions of cognitive impairment were determined
by exploratory factor analysis using ACE-R domain
scores as items., Pearson’s product moment correla-
tions between domains were calculated and the cor-
relation matrix inspected for ill-conditioning (defined
as intercorrelation > 0.8) prior to further analysis.
The correlation matrix was also tested for singular-
ity by Bartlett’s test of sphericity and sampling ade-
quacy confirmed by the Kaiser-Meyer-Olkin test (ade-
quacy defined by KMO > 0.6 for individual domains
and wholemodel). Factor extractionwas performed us-
ing the principal factor method with factors retained
following inspection of the screeplot [22]. In order to
improve interpretability while allowing for correlation
between retained factors, an oblique rotation was used
(direct quartimin). Factor scores were generated by the
regression method [23], and internal consistency was
assessed by Cronbach’s alpha. Higher order structure
was also evaluated by the principle factor method. As-
sessment of latent general factor contributions was per-
formed by Schmid-Leiman orthogonal transformation
using computational methods described by Thomson
in the MacOrtho software package [24,25]. The pro-
portion of test variance attributable to higher and first-
order factors was assessed by McDonald’s ωh mea-
sure [26]. Data are shown as mean ± SD unless other-
wise stated.
3. Results
3.1. Participant characteristics
Case and control groups were matched for age (50.9
± 9.6 vs. 52.0 ± 9.4; p = 0.63), sex (male = 56% vs.
50%; p = 0.62), and years in full-time education (12.9
± 0.3 vs. 13.4 ± 0.7; p = 0.51). Sixty-eight percent
(60/88) of the patient group had secondary progres-
sive MS (SPMS) and thirty-two percent (28/88) pri-
mary progressive MS (PPMS). No patient had experi-
enced a relapse or received treatment with steroids in
the 3-months prior to assessment, and no patients were
excluded from the study. The SPMS group had a higher
mean disease duration than the PPMS group (13.6 ±
7.8 years vs. 9.4± 5.6 years; p = 0.02), but there were
no other differences in demographic or disease charac-
teristics; or in cognitive performance assessed by the
ACE-R and PASAT (Table 1).
3.2. Independent dimensions of cognitive impairment
In order to determine if independent dimensions of
cognitive dysfunction were present, exploratory factor
analysis was performed using ACE-R domain scores
as items. This revealed two dimensions of covariance
that showed significant emphasis for frontal-executive
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Fig. 1. Patterns of cognitive impairment by disease course. Scatterplots for scores of individual patients on the two dimensions of cognitive
impairment identified by factor analysis (D1 & D2). Dashed lines indicate reference ranges for healthy controls (2 SD below the control mean).
Patients in both disease groups show an excess of impairment for language and visuospatial functions (D2), with isolated frontal-executive
impairment (D1) rarely seen (SPMS, Fisher’s exact, p = 0.001; PPMS, Fisher’s exact, p = 0.040).
Table 2
First-order factor analysis of cognitive domain scores
D1 D2
Attention and orientation 0.72 0.10
Fluency 0.62 −0.10
Memory 0.75 −0.01
Language 0.01 0.75
Visuospatial 0.00 0.80
Eigenvalue 2.25 0.41
Two independent dimensions of cognitive impairment are shown
with high factor loading for attention and orientation, fluency, and
recall memory (D1); and language and visuospatial functions (D2)
respectively. ACE-R = Addenbrooke’s Cognitive Examination (Re-
vised).
functions (“D1”: Attention and Orientation, Memory,
and Verbal fluency), and separately for posterior cor-
tical functions (“D2”: Language and Visuospatial; Ta-
ble 2). Both dimensions had high internal consistency
(Cronbach’s alpha = 0.69 and 0.89 respectively). Per-
formance on the PASAT was moderately correlated
with D1 (r = 0.53) but weakly correlated with D2 (r =
0.39).
3.3. Pattern of cognitive impairment
Scatterplots of subject-scores for the two indepen-
dent dimensions of impairment were examined to de-
termine if impairment occurred in a predictable pattern
with respect to primary and secondary progressive pa-
tient groups. A consistent distribution of impairment
was seen (figure), with isolated impairment in poste-
rior cortical functions overrepresented in both SPMS
and PPMS groups (Fisher’s exact test; p = 0.001 and
p = 0.040 respectively).
Table 3
Contribution of general and independent factors to variance in cog-
nitive functions
General factor Independent factors
G D1 D2
Attention and orientation 0.698 0.364 0.048
Fluency 0.443 0.314 −0.053
Memory 0.638 0.383 −0.005
Language 0.659 0.006 0.383
Visuospatial 0.673 0.001 0.397
% Variance explained 74.2 14.2 11.6
Schmid-Leiman solution showing the relative contributions of a gen-
eral factor (G) and independent factors (D1 and D2) to the variance
in ACE-R cognitive domain scores observed in patients with pro-
gressive MS.
3.4. The contribution of a global influence to
cognitive impairment
The contribution of a global influence in cognitive
performance was then assessed by higher-order factor
analysis. This showed evidence of a general factor that
accounted for 74.2% of total variance in cognitive per-
formance. Independent effects of first-order factors D1
and D2 therefore accounted for 14.2% and 11.6% of
total variance respectively (Table 3).
3.5. Differences in the pattern of cognitive
dysfunction by disease course
In order to compare disease groups, separate anal-
yses for SPMS and PPMS were also performed.
Screeplot inspection following initial factor extraction
supported retention of one factor in both analyses. The
cognitive domains with highest factor loading differed
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Table 4
Shared variance in cognitive functions by disease course
SPMS PPMS
Attention and orientation 0.83 0.77
Fluency 0.67 0.14
Memory 0.76 0.62
Language 0.52 0.94
Visuospatial 0.55 0.92
Eigenvalue 2.28 2.73
Factor analysis of ACE-R domain sub-scores by disease course. Ini-
tial extraction supported retention of one factor in both models, un-
rotated factor loadings are therefore shown.
between groups, with the SPMS group having high-
est shared variance in attention, memory and fluency
scores. In contrast, the PPMS group had highest shared
variance in attention, language and visuospatial do-
main scores (Table 4).
4. Discussion
Like those in relapsing-remitting disease, studies of
cognition in progressive MS have typically focused on
impairment in executive functions, recall memory, and
attention; a pattern viewed as archetypal of the dis-
ease [2]. Our study demonstrates the existence of two
independent dimensions of impairment that account
for 55% and 45% respectively of the variance in cogni-
tive function not explained by a global influence. The
first dimension (D1) reflects a well established “core
impairment” of cognitive functions: attention, verbal
fluency, and recall memory. Accordingly, D1 shows
highest correlation with traditional measures of cogni-
tion in MS such as the Paced Auditory Serial Addi-
tions Test (PASAT). In contrast, the second dimension
(D2) reflects impairment of cognitive functions rarely
studied in MS: language and visuospatial abilities. In-
terestingly, while an isolated pattern of language and
visuospatial (D2) dysfunction was observed in some
patients, isolated impairment of frontal-executive (D1)
functions was seen only rarely in SPMS and never in
PPMS.
Our finding of a prominent global influence on cog-
nitive performance is unsurprising when viewed in the
context of a large body of research into human cog-
nition in health. In normal individuals, a general fac-
tor (‘g’) accounts for around 50% of variance in per-
formance across all psychometric tests [27]. The ob-
served ‘g’ of 74.2% in our study may therefore re-
flect a combination of normal biology and global im-
pairment due to disease. Information processing speed
has been proposed as a possible neurobiological mech-
anism underpinning ‘g’ in healthy individuals, and a
reduction of information processing speed represents
an attractive interpretation of the general factor in our
study given recent descriptions in healthy individuals
linking ‘g’ to diffuse white matter tract integrity [28],
a metric known to be markedly impaired in progres-
siveMS [29]. Nevertheless, the remaining 25.8% of in-
dependent variance implies that a clinically significant
burden of dysfunction falls selectively on specific cog-
nitive functions. This independent variance was split
equally between D1 and D2, indicating that their com-
ponents merit equal attention in the clinical assessment
of patients with suspected cognitive impairment due to
MS.
As an observational study of cognitive dysfunction
in progressive MS, our study has limitations. Potential
confounding by physical disabilities is an issue for the
evaluation of all aspects of cognition in MS – regard-
less of the psychometric instrument used, or the cog-
nitive domain in question. Weakness, ataxia, spastic-
ity, and other physical impairments may limit perfor-
mance on tasks involving copying, drawing, or point-
ing. Reduced information processing speed may affect
performance on timed tasks, dysarthria on tasks requir-
ing verbal responses, and fatigue has the potential to
impact on any complex task. These limitations apply
across all existing published work in MS cognition,
but are particularly pertinent to studies of patients with
progressive disease. In this context, the ACE-R offers
an attractive alternative to the traditional MS cogni-
tive batteries, as it has been extensively applied to pa-
tients with neurodegenerative disorders such as PD,
PSP, and MSA, who exhibit similar levels of physi-
cal disability [17,18]. Moreover, recent research sug-
gests high sensitivity of ACE-R components to cogni-
tive dysfunction in MS [30]. Second, despite the best
efforts of regulatory authorities, underrepresentation of
women in clinical research remains a significant chal-
lenge [31]. With reference to existing epidemiological
UK-based data [32], women were underrepresented in
our SPMS cohort (probability of the observed sex ra-
tio = 0.02, two-sided binomial probability test). Given
that all patients referred were recruited to the study, it
is possible that the underrepresentation of female pa-
tients in the SPMS cohort represents bias on behalf of
the referring practitioners.
Although our study does not have the necessary
imaging assessments to define the precise anatomi-
cal substrate of the two independent dimensions iden-
tified by factor analysis, D1 components can be in-
terpreted as representative of frontal-executive (FE)
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functions [33–35]. More tentatively, D2 components
could reflect more posterior, parieto-temporal-occipital
(PTO) functions [36–39]; although it has to be remem-
bered that frontal dysfunction can also be associated
with language impairment. In our PPMS group, im-
pairment of D2 functions was seen with or without im-
pairment of D1, whereas D1 impairment was only seen
together with impairment of D2 functions. The same
distribution was also observed in the SPMS group, al-
though rare isolated impairment in D1 functions was
occasionally seen. This pattern raises the possibility
that language and visuospatial impairment may be typ-
ical of cognitive dysfunction in progressiveMS. More-
over, the absence of isolated frontal-executive dysfunc-
tion in our PPMS cohort is consistent with this pat-
tern of impairment when deficits due to randomly dis-
tributed focal white matter lesions are minimal.
Our findings are of interest in the context of debate
about the contribution of inflammatory processes and
neurodegeneration to the clinical deficits seen in pro-
gressive MS. Although inflammation and neurodegen-
eration co-exist throughout the disease, they assume
shifting prominence dependent upon the clinical stage,
with neurodegeneration assuming greater pathogenic
significance in patients with progressive disease [40].
The mechanistic relationship between these compo-
nents of the disease biology remains debated [10];
however, the relative lack of focal inflammatory white
matter disease in primary progressive (PPMS) com-
pared to secondary progressive MS (SPMS) provides
an opportunity to evaluate the contribution of multi-
focal inflammation. In addition to the absence of iso-
lated frontal-executive impairment in our PPMS group,
group-specific analysis showed low factor loading of
frontal-executive functions (verbal fluency) and high
loading of visuospatial and language domains; a pat-
tern that was reversed in SPMS group. Taken together,
these observations are consistent with a hypothesis that
language and visuospatial impairment may reflect a
predominantly neurodegenerative (or diffuse inflam-
matory) effect and frontal-executive dysfunction a fo-
cal inflammatory effect. Such an interpretation is sup-
ported by Huijbregts et al., who also found verbal flu-
ency to be relatively impaired in SPMS, and spared in
PPMS [13].
Our finding that language and visuospatial impair-
ment has a significant independent contribution to
overall cognitive dysfunction has important implica-
tions for the clinical assessment of patients with pro-
gressive MS. It supports a view that the traditional ap-
proach to cognitive assessment in MS, focussed on
frontal-executive functions, should be complemented
by assessment of more posterior cortical functions in-
cluding language and visuospatial abilities. This can
be achieved using comprehensive batteries such as
the Minimal Assessment of Cognitive Function in MS
(MACFIMS; 90 minutes to administer) [41]. However,
our study also demonstrates that both frontal-executive
and posterior cortical dysfunction can be identified
even by a brief (20 minutes) multidimensional bedside
screening tool such as the ACE-R.
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